30 December 2021 in ScienceRise: Biological Science
The aim. Determination of the need to raise awareness of the population about multivitamins and the criteria for their rational choice. Materials and research methods. To achieve the goal of the study, it was necessary to develop a questionnaire for visitors to pharmacies and carry out an anonymous survey of them. All adult visitors of the pharmacy were attracted to the survey. The developed questionnaire consisted of 3 parts and contained 32 questions processed in the course of our own research. Research results. Among the pharmacy visitors we surveyed, the majority were between the ages of 35–55, approximately equally divided were men and women who mainly lived in the Kiev region (87 %), were not students and did not have educational levels of bachelor or master, and had no relation in health care education. Summarizing the information obtained in the course of processing questionnaires with the answers of visitors to pharmacies, it can be noted that in the surveyed group of respondents there is a certain interest and indifference to the discussed aspects, but quite often there is a lack of knowledge in this regard. Conclusions. In the course of analyzing the results of the questionnaire survey, the level of awareness of the population regarding general information about the pharmacology of multivitamin drugs and the criteria for their correct choice was determined. From the data obtained, it can be concluded that on many issues the respondents showed an insufficient level of knowledge, which justifies the need for additional information about multivitamins, and indicates that better it should be done with participation of a specialist with a pharmaceutical education or physician. Mostly the population lacks knowledge on the issues listed in the second part of the questionnaire, namely, on general information about the biological and pharmacological properties of vitamins. It was found that the information obtained from the Internet or other media, including advertising, has a significant impact on the awareness and decision of the respondents
30 June 2023 in Likars'ka Sprava
Asthenia or asthenic syndrome (AS) is a condition in which a person is characterized by excessive fatigue, marked weakness, mood swings and mainly negative mood. Asthenia is a symptom of many organic and mental diseases. A person usually cannot engage in both physical and mental work for a long time due to prolonged or chronic fatigue. AS can be considered as a universal protective mechanism that accompanies various psychophysiological processes and somatic diseases, which are based on mechanisms of energy deficiency. Being in its essence a protective mechanism that signals the exhaustion of energy resources, AS can become a pathological, extremely disabling condition and even transform into its own nosology - chronic fatigue syndrome, an immune-mediated disease. Therefore, AS is a medical and social problem and requires adequate pharmacological correction. Today, drugs such as: adaptogens of plant and animal origin are used for the treatment of AS and stimulation of physical and mental performance; actoprotectors, antihypoxants; drugs with metabolic and neurotropic effects, B vitamins. The purpose of the work. Assessment of consumption and availability in the pharmaceutical market of Ukraine and analysis of the range of drugs for stimulation of physical and mental performance in the treatment of AS when dispensing over-the-counter drugs for the symptomatic treatment of asthenia. Research methods. Sociological, system-analytical, analytical. Results. A study was conducted to assess consumption and availability on the pharmaceutical market of Ukraine and to analyze the assortment of pharmaceutical products for the dispensing of over-the-counter drugs for the symptomatic treatment of asthenia.
29 February 2024 in ScienceRise: Pharmaceutical Science
Osteoarthritis is one of the most widespread diseases, represents a medical and socio-economic problem and is one of the first places among the causes of long-term disability of the population in the world. Cytokine mechanisms of osteoarthritis development are attracting more and more attention. The aim of the study was to determine the chondroprotective and anti-inflammatory properties of the original recombinant interleukin-1 (IL-1) receptor antagonist (ARIL-1) raleukin on the model of systemic steroid osteoarthritis (SSO) in rats. Materials and methods. The SSO model was reproduced in a modified form by intramuscular three-time administration of dexamethasone at a dose of 7 mg/kg with an interval of one week. Raleukin was injected subcutaneously in a conditionally effective dose of 3 mg/kg for anti-inflammatory activity, and glucosamine (GA) orally in a dose of 50 mg/kg (ED50 for anti-inflammatory activity). Starting from the 28th day of the study and for 4 weeks, the study objects were introduced by the appropriate route once a day. Result. The results of the experiment show that clinical signs of damage to the locomotor system appeared in all animals after three administrations of dexamethasone. Later and before the end of the experiment, a typical clinical picture of the development of SSO was observed, which was confirmed by the results of the study of biochemical markers (mainly in blood serum) of the state of the connective tissue of the experimental animals. Significant changes in the functional status of the animals were noted in rats with SSO who received raleukin starting from the second week of administration. In rats, motor activity increased, tolerance to physical exertion increased, joint condition visually normalised, and appetite increased. When the reference drug GA was administered, the functional state of the animals differed from the control pathology group to a somewhat lesser extent. Besides, raleukin did not reliably differ from GA in its effect on biochemical parameters characterising the state of connective tissue and the content of its main metabolites in the blood serum of rats with steroid osteoarthritis. Conclusions. In the model of systemic steroid osteoarthritis, raleukin contributed to the improvement of functional indicators of the condition of animals and the normalisation of their body weight; namely, it moderately reduced the content of all markers of connective tissue metabolism in the blood serum of animals, especially chondroitin sulfates and sialic acids, which can be explained by the systemic nature of its effect. In terms of its effect on the level of the main metabolites of connective tissue in the blood serum of rats, raleukin prevailed over glucosamine hydrochloride. Thus, the analysis of biochemical data against the background of experimental osteoarthritis allows us to draw a conclusion about the high chondroprotective and anti-inflammatory potential of the recombinant IL-1 receptor antagonist